Maria Mar Hernandez Guillamon Senior Researcher, Neurovascular Research Lab, VHIR. Instituciones de las que forman parte Investigador/a principal Enfermedades Neurovasculares Vall Hebron Institut de Recerca Twitter Email Maria Mar Hernandez Guillamon Twitter Email Instituciones de las que forman parte Investigador/a principal Enfermedades Neurovasculares Vall Hebron Institut de Recerca Senior Researcher, Neurovascular Research Lab, VHIR.
Dr. Mar Hernández-Guillamon has dedicated her career to the study of cerebral amyloid angiopathy (CAA) and other pathologies associated with the deposition of amyloid-beta (Abeta). In 2013, she was awarded by Carlos III Spanish Health Institute with the Miguel Servet contract to establish the Cerebral Amyloidosis line of research at VHIR. Her group has positioned in forefront of the Abeta-pathologies field, studying the molecular mechanisms involved in the Abeta transport and metabolism using in vitro and in vivo models. Her lab has also dedicated to the clinical research and discovery of biomarkers associated with CAA and other cerebrovascular diseases. The translational research developed by Dr. Hernandez-Guillamon's group has allowed the achievement of important aims to date, as demonstrated by the scientific production obtained (h-index= 35, 80 publications, >3700 citations) and the continuous leadership of national and international projects.
Líneas de investigación L5 Cerebral Amyloid Angiopathy Current project: Involment of proteolytic systems in the progression of Cerebral Amyloid Angiopathy Cerebral amyloid angiopathy (CAA) is produced by the accumulation of ß-amyloid protein within the meningeal and brain vessels. It is the second leading cause of cerebral hemorrhages. However, nowadays, factors related to brain bleedings following amyloid deposition are largely unknown. The understanding of the mollecular mechanisms that lead to cerebral hemorrhage may be the basis for future treatments. Previous evidences of our group have shown that Matrix Metal•loproteinases (MMPs) are related to brain bleeding. Now, we aim to investigate the relationship between these proteolytic systems and the appearance of intracraneal hemorrages in CAA. Our study includes: 1) The identification of both tissue and plasma biomarkers for the diagnosis and prognosis of CAA-related hemorrhages. 2) The search of the genetic markers related to proteolytic systems that could determine the risk of suffering a recurrence in CAA. We are studying a cohort of probable CAA patients that have been recruited in Hospital Vall d’Hebron in collaboration with the Stroke Project of the Cerebrovascular Diseases Study Group (Spanish Society of Neurology). 3) The study of MMPs role in ß-amyloid stimulated vascular cells in vitro. Cultured cells of the neurovascular unit are challenged with different ß-amyloid peptides and the implication of MMPs in ß-amyloid cleavage and cell toxicity are studied using cellular and molecular biology methodology. For this purpose, we use the human cerebral endothelial cell line hCMEC/D3, primary cultures of human leptomeningeal smooth muscle cells and rat/mouse glial and neuronal cultures. Thioflavin-S staining of fibillar ß-amyloid within brain vessels of CAA patient’s sections. Related bibliography: 1) Hernández-Guillamon M, Delgado P, Ortega L, Pares M, Rosell A, García-Bonilla L, Fernández-Cadenas I, Borrell-Pagès M, Boada M, Montaner J. Neuronal TIMP-1 release accompanies astrocytic MMP-9 secretion and enhances astrocyte proliferation induced by beta-amyloid 25-35 fragment. J Neurosci Res. 2009 Jul;87(9):2115-25. 2) Rosell A, Ortega-Aznar A, Alvarez-Sabín J, Fernández-Cadenas I, Ribó M, Molina CA, Lo EH, Montaner J. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke. 2006 Jun;37(6):1399-406. 3) Alvarez-Sabín J, Delgado P, Abilleira S, Molina CA, Arenillas J, Ribó M, Santamarina E, Quintana M, Monasterio J, Montaner J. Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke. 2004 Jun;35(6):1316-22. 4) Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, Quintana M, Alvarez-Sabín J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003 Feb 4;107(4):598-603. Collaborations: Mercè Boada Fundació ACE, Barcelona, Spain. www.fundacioace.com/ Jorge Ghiso and Agueda Rostagno Pathology Dept. Langone Medical Center. NYU New York, US. Ignacio Romero Life Science Dept. Open University. Milton Keynes, UK. IP: Maria Mar Hernandez Guillamon Proyectos Papel de la proteína MFGE8 como potencial biomarcador y diana terapéutica en la angiopatía amiloide cerebral IP: Maria Mar Hernandez Guillamon Colaboradores: Berta Paez Montserrat, Kerrie Adrián Campbell, Anna Bonaterra Pastra, Jessica Camacho Soriano, Olalla Pancorbo Rosal Entidad financiadora: Instituto de Salud Carlos III Financiación: 208750 Referencia: PI23/00082 Duración: 01/01/2024 - 31/12/2026 Implication of proteins associated with vascular beta-amyloid in Cerebral Amyloid Angiopathy IP: Maria Mar Hernandez Guillamon Colaboradores: Berta Paez Montserrat, Laia Perez Lasarte Entidad financiadora: FUNDACIÓN JOSEP PALAU FRANCÀS Financiación: 68873.32 Referencia: VHIRFRANCAS/PREDOC/2022 Duración: 01/02/2023 - 31/01/2026 Malalties neurovasculars IP: Anna Rosell Novel Colaboradores: Mercedes Arrue Gonzalo, Joan Montaner Villalonga, Marcel Lamana Vallverdu, Anna Penalba Morenilla, Anna Bonaterra Pastra, Maria Mar Hernandez Guillamon, Olga Maisterra Santos, Maria Pilar Delgado Martínez, Antonio Palasi Franco, Jesús Pizarro Gonzálvez, Paula Garcia Rodriguez, Miguel García Gabilondo, Nicolas Garcia Rodriguez Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca Financiación: 40000 Referencia: 2021 SGR 00656 Duración: 01/01/2022 - 30/06/2025 Malalties neurovasculars IP: Maria Mar Hernandez Guillamon Colaboradores: Judit Álvarez González Entidad financiadora: Instituto de Salud Carlos III Financiación: 65000 Referencia: CM22/00226 Duración: 01/01/2023 - 31/12/2024 Paginación Página actual 1 Página 2 Página 3 Página 4 Página 5 … Siguiente página › Última página »
